NasdaqGM - Nasdaq Real Time Price USD

Mirum Pharmaceuticals, Inc. (MIRM)

Compare
39.12
-2.35
(-5.67%)
At close: 4:00:02 PM EDT
39.12
0.00
(0.00%)
After hours: 4:05:07 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
336,888
336,888
186,374
77,062
19,138
Cost of Revenue
81,643
81,643
47,039
12,374
1,903
Gross Profit
255,245
255,245
139,335
64,688
17,235
Operating Expense
342,851
342,851
248,489
195,908
190,648
Operating Income
-87,606
-87,606
-109,154
-131,220
-173,413
Net Non Operating Interest Income Expense
-519
-519
-1,370
-12,122
-17,224
Other Income Expense
1,213
1,213
-51,900
1,271
106,686
Pretax Income
-86,912
-86,912
-162,424
-142,071
-83,951
Tax Provision
1,030
1,030
991
-6,406
37
Net Income Common Stockholders
-87,942
-87,942
-163,415
-135,665
-83,988
Average Dilution Earnings
--
--
--
-914
--
Diluted NI Available to Com Stockholders
-87,942
-87,942
-163,415
-136,579
-83,988
Basic EPS
-2.08
-1.85
-3.94
-4.01
-2.77
Diluted EPS
-2.08
-1.85
-3.94
-4.02
-2.77
Basic Average Shares
42,479.52
47,522.59
40,885.12
33,839.07
30,321.72
Diluted Average Shares
42,479.52
47,522.59
40,885.12
33,982.49
30,321.72
Total Operating Income as Reported
-87,606
-87,606
-109,154
-131,220
-173,413
Total Expenses
424,494
424,494
295,528
208,282
192,551
Net Income from Continuing & Discontinued Operation
-87,942
-87,942
-163,415
-135,665
-83,988
Normalized Income
-87,942
-87,942
-124,644.96
-136,530.14
-83,453.64
Interest Income
13,792
13,792
13,735
3,857
366
Interest Expense
14,311
14,311
15,105
15,979
17,590
Net Interest Income
-519
-519
-1,370
-12,122
-17,224
EBIT
-72,601
-72,601
-147,319
-126,092
-66,361
EBITDA
-48,972
-48,972
-136,490
-122,854
-65,766
Reconciled Cost of Revenue
81,643
81,643
47,039
12,374
1,903
Reconciled Depreciation
23,629
23,629
10,829
3,238
595
Net Income from Continuing Operation Net Minority Interest
-87,942
-87,942
-163,415
-135,665
-83,988
Total Unusual Items Excluding Goodwill
--
--
-49,076
906
-732
Total Unusual Items
--
--
-49,076
906
-732
Normalized EBITDA
-48,972
-48,972
-87,414
-123,760
-65,034
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
-10,305.96
40.86
-197.64
12/31/2021 - 7/18/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BPMC Blueprint Medicines Corporation
80.27
-2.17%
 
VERA Vera Therapeutics, Inc.
21.81
-0.95%
 
CGEM Cullinan Therapeutics, Inc.
7.58
-2.70%
 
RARE Ultragenyx Pharmaceutical Inc.
33.16
-2.21%
 
CRNX Crinetics Pharmaceuticals, Inc.
26.85
-2.93%
 
MLTX MoonLake Immunotherapeutics
33.97
-5.59%
 
NUVL Nuvalent, Inc.
61.99
-4.19%
 
MRUS Merus N.V.
38.62
-2.38%
 
PTGX Protagonist Therapeutics, Inc.
40.89
-3.95%
 
IDYA IDEAYA Biosciences, Inc.
15.77
-0.06%